New Heart-Protection Use for Mounjaro in Type 2 Diabetes

Mounjaro (tirzepatide) is a once-weekly subcutaneous injection. On the US Prescribing Information (Recent Major Changes 08/2026) it is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.

This article is about the new adult CV risk-reduction pathway. The sugar-control indication (including ages 10+) remains on the same USPI but is not the expansion being walked here.

This is a traditional FDA supplemental approval of a product first approved in 2022.

Distinct path — not this label: Zepbound (tirzepatide) for chronic weight management is a separate branded label/indication conversation. Trulicity (dulaglutide) was the active comparator in SURPASS-CVOT — not this product. Other GLP-1 medicines with CV claims have separate labels. Today’s approved US tirzepatide CV risk-reduction route for adults with type 2 diabetes at high CV risk is Lilly Mounjaro (NDA 215866/S-044).

The FDA approved NDA 215866/S-044 (with related S-045 dosing clarification) effective on the letter date 27 August 2026 (electronic signature Mahtab Niyyati; Lilly public announcement dated 28 August 2026). Applicant: Eli Lilly and Company, Indianapolis, IN. Letter attention: Jacob Monroe, PhD and Asavari Wagle. USPI Revised 08/2026. Reference ID on letter 5860252.

Where this is taking place

Approved prescription route today: United States — FDA-labelled Mounjaro for adults with type 2 diabetes at high CV risk, prescribed through a diabetes / endocrinology / cardiology / primary-care clinician already able to prescribe weekly tirzepatide pens or vials, with the usual titration and safety monitoring. Existing US commercial supply and Lilly support channels apply. This is a prescription diabetes / CV-risk conversation — not a DIY import and not an obesity-only Zepbound claim.

Outside the United States: At the time of writing, no confirmed Health Canada Product Monograph text, European Commission marketing authorisation, MHRA licence, TGA listing, Swissmedic authorisation, or PMDA/MHLW licence for this CV indication. Existing foreign Mounjaro licences for glycemic control, if any, are not automatically this expansion. SURPASS-CVOT sites in other countries are not a foreign CV label. Do not import on your own.

SURPASS-CVOT — NCT04255433 — Phase 3, event-driven, multicenter, international, randomized, double-blind, active-comparator (dulaglutide 1.5 mg weekly) study. As described on the USPI: adults with inadequately controlled type 2 diabetes and established CV disease. CT.gov status at the time of writing: completed. Actual enrolment 13,299. Expanded access: CT.gov reports expanded access: none listed. Locations span many countries including the United States and Canada among others. A completed CVOT supports the label. That is not open new enrolment. Canadian trial sites are not a Canadian CV Product Monograph.

The practical prescription route in the US is a clinician who can confirm type 2 diabetes and high CV risk, review contraindications (personal/family history of medullary thyroid carcinoma or MEN2; serious hypersensitivity), plan weekly titration, monitor gastrointestinal and retinopathy watchpoints, and arrange payer / Lilly support logistics.

Approval matrix

Access by country

• United States: Ask a diabetes / endocrinology / cardiology / primary-care clinician about FDA-labelled Mounjaro for this heart-protection pathway. Labelled August 2026 to reduce MACE (CV death, non-fatal MI, or non-fatal stroke) in adults with type 2 diabetes at high risk for these events. Recommended dosage family: start 2.5 mg subcutaneously once weekly; if additional glycemic control is needed, increase in 2.5 mg increments after at least 4 weeks on the current dose; maximum 15 mg once weekly. Example single-dose pen 4-packs include NDC 0002-1506-80 (2.5 mg), 0002-1495-80 (5 mg), 0002-1484-80 (7.5 mg), 0002-1471-80 (10 mg) — confirm the strength on the carton with the pharmacy. Suspected adverse reactions: Eli Lilly 1-800-LillyRx (1-800-545-5979) or FDA MedWatch 1-800-FDA-1088. No list price or copay dollars in this article. This is US commercial labelled supply, not a DIY import.

• Canada: This CV Mounjaro authorisation is not confirmed. Ask the Canadian diabetes clinic what legal paths exist in Canada when a Canadian label for this CV use is not confirmed. An existing Canadian glycemic label, if present, is not automatically this expansion.

• European Union / United Kingdom / Australia / Japan / other countries: Regulator authorisation for this CV use is not confirmed on the sources checked. Completed trial sites are not a foreign marketing authorisation for the new use. Do not import on your own.

• If your regulator has not authorised this use: do not import on your own. Ask the local clinician about documented special-access / named-patient rules, referral to a centre in a labelled country, or waiting — without treating a US pen as a foreign pack for this expansion.

Who is eligible (from the US label)

This is an adult type 2 diabetes + high CV risk conversation on the Prescribing Information for the new pathway — not a claim that Mounjaro beat dulaglutide on MACE, and not a collapse into the Zepbound obesity label.

United States (USPI, revised August 2026):

• Indication (this article): Reduce the risk of major adverse CV events (CV death, non-fatal MI, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
• Recommended dosage: Start 2.5 mg SC once weekly; titrate by 2.5 mg after ≥4 weeks as needed; max 15 mg weekly.
• Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); known serious hypersensitivity to tirzepatide or excipients.
• Boxed warning: Tirzepatide causes thyroid C-cell tumors in rats; human relevance unknown; counsel on symptoms of thyroid tumors.
• Other warnings (highlights): Acute pancreatitis; hypoglycemia with insulin/secretagogues; hypersensitivity; acute kidney injury from volume depletion; severe gastrointestinal reactions (not recommended in severe gastroparesis); diabetic retinopathy complications in patients with history of diabetic retinopathy; acute gallbladder disease; pulmonary aspiration risk with anesthesia/deep sedation; never share a KwikPen between patients.
• Most common adverse reactions (≥5% on glycemic program labeling): nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.
• Pediatrics: Glycemic control labelled for ages 10+; the CV indication text on Highlights/section 1 is written for adults.
• SURPASS-CVOT population (USPI): Adults ≥40 years with T2D and established CV disease; HbA1c 7.0–10.5%; BMI ≥25; mean age 64; mean diabetes duration 15 years; baseline CAD 65%, prior MI 47%, prior stroke 19%, heart failure history 20%.

Not labelled on the sources checked for this article:

• Proven superiority to dulaglutide on MACE (superiority not established).
• This CV expansion in Canada, the EU, UK, Japan, Australia, or Switzerland (not confirmed here).
• Using the Zepbound obesity brand as this T2D CV label.
• Treating NCT04255433 as open commercial enrolment.

What the pivotal study showed (Prescribing Information)

Use the Prescribing Information for a prescription conversation. Journals are supportive reading.

SURPASS-CVOT — NCT04255433 (USPI section 14.6 / Table 10):

Noninferiority of Mounjaro to dulaglutide for MACE-3: p=0.007. Superiority to dulaglutide was not established. Median study observation time 210.1 weeks. Component and all-cause death rows were not controlled for family-wise type I error on the USPI footnote, so they are not independently proven labelled wins.

The CT.gov status is completed. The approved CV prescription route is not open pivotal enrolment.

How it is taken (US label)

Who / research team (primary sources only)

• Sponsor / applicant: Eli Lilly and Company (sNDA letter; USPI).
• Letter attention: Jacob Monroe, PhD and Asavari Wagle, Global Regulatory Affairs (NDA 215866/S-044/S-045 letter).
• Pivotal trial: SURPASS-CVOT (NCT04255433) — USPI section 14.6.
• Patient / AE contact (label): Eli Lilly and Company 1-800-LillyRx (1-800-545-5979); FDA MedWatch 1-800-FDA-1088.
• Names and phones below are limited to what appears on the Prescribing Information, FDA supplement approval letter, ClinicalTrials.gov, and clearly labelled company materials.

Sources

1. FDA — NDA 215866/S-044 and S-045 Supplement Approval Letter for Mounjaro (tirzepatide) (27 Aug 2026; Reference ID 5860252).
2. Eli Lilly — Mounjaro US Prescribing Information (Revised 08/2026), including section 14.6 SURPASS-CVOT.
3. Eli Lilly — FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk… (28 Aug 2026 announcement).
4. ClinicalTrials.gov — NCT04255433 (SURPASS-CVOT).
5. Health Canada DPD — Mounjaro DIN listings (glycemic pens; CV PM text not confirmed at the time of writing).

Not medical advice. Talk with a clinician who knows the full history before any treatment decision. Authorized is not funded.